Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: Methods' comparison

Leukemia Research

Volumn 34, Issue 6, 2010, Pages 714-717

  Awidi, Abdalla ^a   Salem, Isam I ^b   Najib, Naji ^b   Mefleh, Razan ^a   Tarawneh, Bothainah ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

^b International Pharmaceutical Research Center Amman   (Jordan)

Author keywords

Chronic myeloid leukemia; HPLC; LCMSMS; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

IMATINIB;

ACCURACY; ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; FEMALE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION;

ADULT; ANTINEOPLASTIC AGENTS; BLOOD CHEMICAL ANALYSIS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CIRCADIAN RHYTHM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET; TANDEM MASS SPECTROMETRY;

EID: 77952093186     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.005     Document Type: Article

References (10)

1. Hochhaus A., Druker B., Sawyers C., et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008, 111:1039-1043.
2. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
3. Mahon F.X., Belloc F., Lagarde V., et al. MDR1 gene over expression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101:2368-2373.
4. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
5. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
6. Bakhtiar R., Lohne J., Ramos L., et al. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002, 768:325-340.
7. Bakhtiar R., Khemani L., Hayes M., et al. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2002, 28(6):1183-1194.
8. le Coutre P., Kreuzer K.A., Pursche S. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004, 53:313-323.
9. Widmer N., Béguin A., Rochat B. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B 2004, 803:285-292.
10. Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); May 2001.